However, the limited efficacy of RTS,S, (RTS,S Clinical Trials Partnership, 2015) particularly against severe malaria (RTS,S Clinical Trials Partnership, 2015), has motivated the search for additional vaccine candidate antigens, including blood-stage Pf-schizont egress antigen-1 (PfSEA-1A) (Raj et al., 2014) and Pf-glutamic acid-rich protein (PfGARP) (Raj et al., 2020). Here, CNGB1 is linked to malaria.